Abstract 5220
Background
The Clustered Regularly Interspaced Short Palindromic Repeats/Cas9 system (CRISPR/Cas9 system), is the defense mechanism in Streptococcus pyogenes against viruses, now it is widely used by researchers as a precise gene editing tool that allows a targeted genomic editing with the least possible off targets. Colorectal cancer (CRC) has recently become a devastating disease with mortality rate exceeded 9% in 2018, where the survival rate worsens once it metastasizes to vital organs such as the liver or lungs. Chemokines are one of the key players that promote cancer cell metastasis in some types of cancers, including colorectal cancer, where increasing evidence shows that CRC accumulates invasive and metastatic capacities through tumor microenvironment. In the light of this, we aimed at understanding the tumor microenvironment to achieve a comprehensive therapy, aiming in preventing early metastasis.
Methods
Microarray was done by our research group on early metastasized CRC cells to liver in a group of rats with CRC. In silico sgRNA CRISPR designing tools were used to design a sgRNA targeting C-C motif chemokine ligand 4 (CCL4) gene. The insert was ligated into a Cas9 expressing plasmid and transformed into E.coli. The Plasmid was then extracted and sequenced. CRC cells were transfected with the cloned plasmid. Functional assays were performed.
Results
Microarray results showed that CCL4 was highly expressed in early metastasized CRC cells to liver that gives a hypothesis that it has a role in cancer progression. Sequencing results confirmed a successful sgRNA insertion into the Cas9 plasmid. In addition, knocking out the expression of CCL4 in CRC cells significantly inhibited the cellular metabolic activity compared to cells transfected with empty plasmid. Furthermore, the ability of CRC cells to proliferate and to form colonies was dramatically decreased in response to CCL4 knockout in comparison to that transfected with empty plasmid.
Conclusions
CCL4 has oncogenic effect on CRC by its positive effect on cell proliferation properties and metabolic activity. The results indicate that CCL4 may act as a promising target for further studies to reveal its downstream impact on CRC progression.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Hassan Adwan, German University in Cairo, Cairo, Egypt.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5694 - Findings from a new specialist remote Counselling Service for Neuroendocrine Neoplasm (NEN) patients and family members
Presenter: Catherine Bouvier
Session: Poster Display session 2
Resources:
Abstract
4725 - Hematologic malignancies in temozolomide-treated metastatic pancreatic neuroendocrine tumors
Presenter: Nicole Balmaceda
Session: Poster Display session 2
Resources:
Abstract
5842 - Efficacy and toxicity of combination chemotherapy with cyclophosphamide, vincristine and an anthracycline in patients with metastatic extrapulmonary neuroendocrine carcinoma
Presenter: Leonidas Apostolidis
Session: Poster Display session 2
Resources:
Abstract
1543 - An Australian multi-centre experience of the use of peptide receptor radionuclide therapy for bronchial carcinoid tumours.
Presenter: Lisi Lim
Session: Poster Display session 2
Resources:
Abstract
4175 - Extra-pulmonary (EP) high grade (HG) neuroendocrine carcinoma (NEC): real-life outcomes of fifty-eight patients from a Portuguese cancer center.
Presenter: Rita Conde
Session: Poster Display session 2
Resources:
Abstract
3274 - Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNET)
Presenter: Shira Sherman
Session: Poster Display session 2
Resources:
Abstract
3534 - HORMONET: Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression
Presenter: Milton Barros
Session: Poster Display session 2
Resources:
Abstract
2137 - Clinical utility of Metabolic Tumor Volume in Papillary Thyroid Carcinoma
Presenter: Norihiko Takemoto
Session: Poster Display session 2
Resources:
Abstract
3864 - Correlation of thyroglobulin (Tg) oscillations with progression-free survival (PFS) in patients with radioactive iodine-refractory (RAI-R) differentiated thyroid carcinoma (DTC) treated with multikinase inhibitors (MKI).
Presenter: Jorge Hernando Cubero
Session: Poster Display session 2
Resources:
Abstract
2820 - Analytical validation of a thyroid cancer diagnostic method based on the relative quantification of CLDN10, HMGA2 and LAMB3 expression
Presenter: Mateus Barrosfilho
Session: Poster Display session 2
Resources:
Abstract